VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA
Vaccine Information
  • Vaccine Name: B. abortus and B. melitensis mutants with unmarked deletion of asp24, virB2, or manBA
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Type: Aerosal Vaccine
  • Antigen: The vaccines tested in this study include B. abortus unmarked mutants BAΔasp24, BAΔvirB2, and BAΔmanBA, and B. melitensis unmarked mutants BMΔasp24, BMΔvirB2, and BMΔmanBA (Kahl-McDonagh et al., 2007).
  • asp24 gene engineering:
  • virB2 gene engineering:
  • manA gene engineering:
  • manB gene engineering:
  • Preparation: Each vaccine consisted of 5 × 10^7 CFU/ml in a chamber nebulizer, which is thousands of organisms per dose. The bacteria were introduced in Farrell's medium: TSA supplemented with 5 mg/liter nalidixic acid, 25,000 IU/liter bacitracin, 100 mg/liter cycloheximide, 5000 IU/liter polymyxin B sulfate, 20 mg/liter vancomycin, 100,000 IU/liter nystatin 10% (vol/vol) horse serum, and 2% (wt./vol.) dextrose (Kahl-McDonagh et al., 2007).
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of four or five female 6- to 8-week-old BALB/c mice were vaccinated via i.p. injection of 1 × 10^6 CFU/ml of unmarked deletion mutant or PBS for naïve controls (Kahl-McDonagh et al., 2007).
  • Persistence: Mice receiving a dose of 5 × 10^7 CFU/ml had lung colonization with B. abortus strain 2308 that gradually increased over the first 4 weeks postchallenge, then gradually decreased over the following 4 weeks to 90% of the maximum value. Despite this slight decrease, colonization by the organism in the other tissues was consistent with a chronic infection. Colonization of the liver, although barely detectable at 1 week postchallenge, steadily increased over the first 4 weeks postchallenge and then declined negligibly between weeks 4 and 8. The spleens of infected mice displayed a colonization pattern similar to that of the livers, although the total number of CFU recovered was consistently higher. Spleen colonization increased between weeks 4 and 8, consistent with a persistent infection (Kahl-McDonagh et al., 2007).
  • Side Effects: Mice receiving a dose of 5 × 10^7 CFU/ml had lung colonization with 2308 that gradually increased over the first 4 weeks postchallenge, then gradually decreased over the following 4 weeks to 90% of the maximum value. Despite this slight decrease, colonization by the organism in the other tissues was consistent with a chronic infection. Colonization of the liver, although barely detectable at 1 week postchallenge, steadily increased over the first 4 weeks postchallenge and then declined negligibly between weeks 4 and 8. The spleens of infected mice displayed a colonization pattern similar to that of the livers, although the total number of CFU recovered was consistently higher. Spleen colonization increased between weeks 4 and 8, consistent with a persistent infection (Kahl-McDonagh et al., 2007).
  • Challenge Protocol: BALB/c mice were challenged with an aerosol chamber dose of 5 × 10^9 CFU/ml of the homologous wild-type strain at 20 weeks postvaccination. Four weeks after the virulent challenge (corresponding to 24 weeks postvaccination), the mice were euthanized and the recovery of the challenge orgainsm was measured (Kahl-McDonagh et al., 2007).
  • Efficacy: The bacterial burden in the spleen following aerosol challenge was reduced 2.02 U by vaccination with BAΔasp24 and by 0.86 U by vaccination with BAΔvirB2 relative to the burden in naïve mice. The rough BAΔmanBA mutant was unable to elicit significant protective immunity relative to the immunity of naïve mice. At 24 weeks postvaccination, less protection was observed in the lungs of mice vaccinated with BAΔasp24 and BAΔvirB2, although the protection was significantly greater than that observed for naïve controls. The rough mutant, BAΔmanBA, protected mouse lungs to a lesser degree, which was not significant(Kahl-McDonagh et al., 2007) .
References
Kahl-McDonagh et al., 2007: Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infection and immunity. 2007; 75(10); 4923-4932. [PubMed: 17664263].